Serum proteins as drug carriers of anticancer agents: A review

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 5, Issue 4, 1998, Pages 281-299

  Kratz, Felix ^a   Beyer, Ulrich ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Anticancer Chemotherapy; Drug Delivery Systems; Low Density Lipoprotein; Protein Conjugates; Serum Albumin; Transferrin; Tumor Targeting

Indexed keywords

ABRIN; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CRM 103; CRM 107; CYTOTOXIC AGENT; DAUNORUBICIN; DIPHTHERIA TOXIN; DOXORUBICIN; DRUG CARRIER; FLOXURIDINE; GELONIN; HIGH DENSITY LIPOPROTEIN; HUMAN SERUM ALBUMIN; LOW DENSITY LIPOPROTEIN; METHOTREXATE; MITOMYCIN C; OVOMUCOID; PACLITAXEL; PLASMA PROTEIN; RIBONUCLEASE A; RICIN A; RUTHENIUM COMPLEX; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VINCRISTINE; ZINOSTATIN;

BIOACCUMULATION; BLOOD VESSEL PERMEABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; LYMPHATIC DRAINAGE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0032421248     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.3109/10717549809065759     Document Type: Review

References (164)

1. Alaupovic, P. 1996. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263:32-60.
2. Allen, T. M., and Chonn, A. 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial. FEBS Lett. 223:42-46.
3. Anderson, R. G. W., Brown, M. S., and Goldstein, J. L. 1981. Inefficient internalization of receptor-bound low density lipoprotein in human carcinoma A-431 cells. J. Cell Biol. 88:441-452.
4. Andersson, C., Iresjo, B. M., and Lundholm, K. 1991. Identification of tumor sites for increased albumin degradation in sarcoma-bearing mice. J. Surg. Res. 50:156-162.
5. Aulbert, E. 1986. Transferrinmangelanämie bei malignen Tumorerkrankungen. New York: Georg Thieme Verlag Stuttgart.
6. Babson, A. L., and Winnick, T. 1954. Protein transfer in tumor-bearing rats. Cancer Res. 14:606-611.
7. Bailey, S., Evans, R. W., Garrat, R. C., Gorinsky, B., Hasnain, S., Horsburgh, C., Jhoti, H., Lindley, P. F., Mydin, A., Sarra, R., and Watson, J. L. 1988. Molecular structure of serum transferrin at 3.3 Å resolution. Biochemistry 27: 5804-5812.
8. Barabas, K., Sizensky, J. A., and Faulk, W. P. 1992. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J. Biol. Chem. 267:9437-9442.
9. Bejaoui, N., Page, M., and Noel, C. 1991. Cytotoxicity of transferrin-daunorubicin conjugates. Anticancer Res. 11:2211-2213.
10. Bergamaschi, G., Cazzola, M., Dezza, L., Savino, E., Consonni, E., and Lappi, D. 1988. Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). Br. J. Haematol. 68:379-384.
11. Beyer, U., Roth, T., Schumacher, P., Maier, G., Unold, A., Frahm, A. W., Fiebig, H. H., Unger, C., and Kratz, F. 1998. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. J. Med. Chem., 41:2701-2708.
12. Bostik, J., Bures, L., Spundova, M., and Rehak, L. 1988. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanona B16 by human serum albumin-methotrexate. Neoplasma 35:343-349.
13. Brock, J. H. 1985. Transferrins. In Metalloproteins, Part 2: Metal Proteins with Nonredox Roles, ed. P. M. Harrison, 183-263, Weinheim: Verlag Chemie.
14. Bures, L., Bostik, J., Motycka, K., Spundova, M., and Rehak, L. 1988. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing. Neoplasma 35:329-342.
15. Bures, L., Lichy, A., Bostik, J., and Spundova, M. 1990. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy V. Alternative methods for preparation of serum albumin-methotrexate derivative. Neoplasma 37:225-231.
16. Butler, T. P., Grantham, F. H., and Gullino, P. M. 1975. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res. 35:3034-3088.
17. Cantafora, A., and Blotta, I. 1996. Neutral lipids production, transport, utilization. Anticancer Res. 16:1441-1450.
18. Cazzola, M., Bergamaschi, G., Dezza, L., and Arosio, P. 1990. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 75:1903-1919.
19. Chitambar, C. R., and Seligman, P. A. 1986. Effect of different transferrin forms on transferrin-receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest. 78:1538-1546.
20. Chitambar, C. R., and Zivkovic, Z. 1987. Uptake of gallium-67 by human leukemic cells, demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res. 47:3929-3934.
21. Chitambar, C. R., Matthaeus, W. G., Antholine, W. E., Graff, K., and O'Brien, W. J. 1988. Inhibition of leukemic HL60 cell growth by transferrin-gallium, effects on ribonucleotide reductase and demonstration of drug synergy with hydroxy urea. Blood 72:1930-1936.
22. Chu, B. C. P., and Howell, S. P. 1981. Differential toxicity of carrier-bound methotrexate toward human lymphocytes, marrow, and tumor cells. Biochem. Pharmacol. 30:2545-2552.
23. Chu, B. C. F., and Whitely, J. M. 1977. High molecular weight derivatives of methotrexate as chemotherapeutic agent. Mol. Pharmacol. 13:80-88.
24. Chu, B. C. F., and Whitely, J. M. 1979. Control of solid tumor metastasis with a high-molecular-weight derivative of methotrexate. J. Natl. Cancer Inst. 62: 79-82.
25. Chu, B. C. F., and Whitely, J. M. 1980. The interaction of carrier-bound methotrexate with L1210 cells. Mol. Pharmacol. 17:382-387.
26. Chun, P. W., Brumbaugh, E. E., and Shireman, R. B. 1986. Interaction of human low density lipoprotein and apolipoprotein-B with ternary lipid microemulsion. Biophys. Chem. 25:223-241.
27. Colombatti, M., Bisconti, M., Dell'Arciprete, L., Gerosa, M. A., and Tridente, G. 1988. Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int. J. Cancer 42:441-448.
28. Colombatti, M., Dell'Arciprete, L., Chignola, R., and Tridente, G. 1990. Carrier protein-monensin conjugates: Enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res. 50:1385-1391.
29. De Smidt, P. C., and van Berkel, T. J. C. 1990. Prolonged serum half life of antineoplastic drugs by incorporation into the low density lipoprotein. Cancer Res. 50:7476-7482.
30. Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., and Cattel, L. 1997. Preparation, characterization, and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Controlled Release 47:293-304.
31. Drevs, J., Hofmann, I., Mormé, D., Unger, C., and Kratz, F. 1998. Superior in vivo efficacy of an acid-sensitive albumin conjugate of adriamycin compared to the parent compound in murine renal cell carcinoma. Drug Del., submitted.
32. Duncan, R., and Spreafico, F. 1994. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27: 290-306.
33. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I. C., Lloyd, J. B., and Kopecek, J. 1988. Anticancer agents coupled to N(2-hydroxypropyl) methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57:147-156.
34. 68Ga citrate. J. Nucl. Med. 10:103-105.
35. Eley, J. G., Halbert, G. W., and Florence, A. T. 1990a. Incorporation of prednimustine into low density lipoprotein: Activity against P388 cells in tissue culture. Int. J. Pharm. 65:219-224.
36. Eley, J. G., Halbert, G. W., and Florence, A. T. 1990b. The incorporation of estramustine into low density lipoprotein and its activity in tissue culture. Int. J. Pharm. 63:121.
37. Elliott, R. L., Elliott, M. C., and Head, J. F. 1990. Preliminary results on 11 advanced breast cancer patients treated with cisplatin complexed to human transferrin. Breast Cancer Res. Treat. 16:169.
38. Elliott, R. L., Stjernholm, R., and Elliott, M. C. 1988. Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. Cancer Detect. Prev. 12:469-480.
39. Faulk, W. P., Taylor, C. G., Yeh, C. J., and McIntyre, J. A. 1990. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. Mol. Biother. 2:57-60.
40. Filipowska, D., Filipowska, T., Morelowska, B., Kazanowska, W., Laudanski, T., Lapinjoki, S., Akerlund, M., and Breeze, A. 1992. Treatment of cancer patients with a low-density lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother. Pharmacol. 29:396-400.
41. Firestone, R. A. 1994. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem. 5:105-113.
42. Firestone, R. A., Pisano, J. M., Falck, J. R., McPhaul, M. M., and Krieger, M. 1984. Selective delivery of cytotoxic compounds to cells by the LDL pathway. J. Med. Chem. 27:1037-1043.
43. Fiume, L., Di Stefano, G., Busi, C., Mattioli, A., Bonino, F., Torrani-Cerenziana, M., Verme, G., Rapicetta, M., Bertini, M., and Gervasi, G. B. 1997. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J. Virol. Hepat. 4:363-370.
44. Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., and Starzyk, R. M. 1991. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA 88:4771-4775.
45. Fritzer, M., Barabas, K., Szüts, V., Berczi, A., Szekeres, T., Faulk, W. P., and Goldenberg, H. 1992. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int. J. Cancer 52:619-623.
46. Gabizon, A., and Papahadjopoulous, D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85:6949-6953.
47. Gabor, F., Wollmann, K., Theyer, G., Haberl, I., and Hamilton, G. 1994. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Anticancer Res. 14: 1943-1950.
48. Gal, D., MacDonald, P. C., Porter, J. C., and Simpson, E. R. 1981a. Cholesterol metabolism in cancer cells in monolayer culture: III. Low-density lipoprotein metabolism. Int. J. Cancer 28:315-319.
49. Gal, D., Ottashi, M., MacDonald, P. C., Buschbaum, H. J., and Simpson, E. R. 1981b. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasm. Am. J. Obstet. Gynecol. 139:877-885.
50. Gal, D., Simpson, E. R., Porter, J. C., and Snyder, J. M. 1982. Defective internalization of low density lipoprotein in epidermoid cervical cancer cells. J. Cell Biol 92:597-603.
51. Ginsburg, G. S., Walsh, M. T., Small, D. M., and Atkinson, D. 1984. Reassembled plasma low density lipoproteins. J. Biol. Chem. 259:6667-6673.
52. Goldstein, J. L., and Brown, M. S. 1977. The low-density lipoprotein pathway and its relation to artherosclerosis. Ann. Rev. Biochem. 46:897-930.
53. Greenfield, L., Johnson, V. G., and Youle, R. L. 1987. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238:536-539.
54. Greenfield, R. S., Kaneko, T., Daues, A., Edson, M. A., Fitzgerald, K. A., Olech, L. J., Grattan, A., Spitalny, G. L., and Braslawsky, G. R. 1990. In vitro evaluation of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 50:6600-6607.
55. Gupta, P. K., and Hung, C. T. 1989b. Albumin microspheres II: Application in drug delivery. J. Microencapsulation 6:427-462.
56. Gupta, P. K., and Hung, C. T. 1989a. Albumin microspheres I: Physiochemical characteristics. J. Microencapsulation 6:463-472.
57. Hall, W. A., Godal, A., Juell, S., and Fodstad, O. 1992. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J. Neurosurg. 76:838-844.
58. Hortung, G., Stehle, G., Sinn, H., Schrenk, H. H., Heeger, S., Kränzle, D., Fiebig, H. H., Maier-Borst, W., Heene, D. L., and Queiβler, W. 1997. Phase I-trial of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients. ECCO 9. Eur. J. Cancer S249:1129.
59. He, X. M., and Carter, D. C. 1992. Atomic structure and chemistry of human serum albumin. Nature. 358:209-215.
60. Henriksson, P., Ericsson, S., Stege, R., Ericsson, M., Rudling, M., Berglund, R., and Angelin, B. 1989. Hypocholesterolemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet II: 1178-1180.
61. Ho, Y. K., Smith, R. G., Brown, M. S., and Goldstein, J. L. 1978. Low density lipoprotein (LDL) receptor activity in human acute myelogenous leukemic cells. Blood 52:1099-1114.
62. Hoshino, T., Misaki, M., Yamamoto, M., Shimizu, H., Ogawa, Y., and Toguchi, H. 1994. In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. J. Pharm. Sci. 84:216-221.
63. Hynds, S. A., Welsh, J., Stewart, J. M., Jack, A., Soulop, M., McArdle, C. S., Calmann, K. C., Packard, C. J., and Shepherd, J. 1984. Low-density lipoprotein metabolism in mice with soft tissue tumours. Biochim. Biophys. Acta 795:589-595.
64. Isaacsohn, J. L., Lees, A. M., Lees, R. S., Strauss, H. W., Barlaikovach, M., and Moore, T. J. 1986. Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism 35:364-366.
65. Ishiguro, K., Ho, P. T., and Sartorelli, A. C. 1992. Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression. Somat. Cell. Mol. Genet. 18:45-63.
66. Iwanik, M. J., Shaw, K. V., Leswith, B. J., Yanovich, S., and Shaw, J. M. 1984. Preparation and interaction of a low-density lipoprotein daunomycin complex with P388 leukemic cells. Cancer Res. 44:1206-1215.
67. Jain, R. K. 1987a. Transport of molecules across tumor vaculature. Cancer Metast. Rev. 6:559-593.
68. Jain, R. K. 1987b. Transport of molecules in the tumor interstitium: A review. Cancer Res. 47:3039-3051.
69. Jeffries, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., and Mason, D. Y. 1984. Transferrin receptor on endothelium of brain capillaries. Nature 312:162-163.
70. Johnson, V. G., Wilson, G., Greenfield, L., and Youle, R. J. 1988. The role of the diphtheria toxin receptor in cytosol translocation. J. Biol. Chem. 263: 1295-130.
71. Keppler, B. K., Lipponer, K.-G., Stenzel, B., and Kratz, F. 1993. New tumor-inhibiting ruthenium complexes. In Metal Complexes in Cancer Chemotherapy, ed. B. K. Keppler, 187-220, Verlag Chemie, VCH, Weinheim: Verlag Chemie, VCH.
72. Kerr, D. J., Hynds, S. A., Shepherd, J., Packard, C. J., and Kaye, S. B. 1988. Comparative cellular uptake an cytotoxicity of a complex of daunomycinlow density lipoprotein in human squamous lung tumour cell monolayers. Biochem. Pharmacol. 37:3981-3986.
73. Kohgo, Y., Kondo, H., Kato, J., Sasaki, K., Tsushima, N., Nishisato, T., Hirayama, M., Fujikawa, K., Shintani, N., and Mogi, Y. 1990. Kinetics of internalization and cytotoxicity of transferrin-neocarzinostatin conjugate in human leukemia cell line, K562. Japan. J. Cancer Res. 81:91-99.
74. Kohgo, Y., Niitsu, Y., Nishisato, T., Urushizaki, Y., Kondo, H., Fukushima, M., Tsushima, M., and Urushizaki, I. 1985. Transferrin receptor of tumor cells - potential tools for diagnosis and treatment of malignancies. In Proteins of Iron Storage and Transport, eds. G. Spik, J. Montreuil, R. R. Crichton, and J. Mazurier, 155-169, Amsterdam: Elsevier Science Publishers.
75. Kornfeld, S. B., Leonard, J. E., Mullen, M. D., and Taetle, R. 1991. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas. Cancer Res. 51:4316-4322.
76. Kratz, F. 1993. Interactions of antitumour metal complexes with serum proteins. Perspectives for anticancer drug development. A review. In Metal Complexes as Antitumour Agents, ed. B. K. Keppler, 392-429, Verlag Chemie Weinhein.
77. Kratz, F. 1995. Drug targeting in der antitumoralen Chemotheraple. Antigene und Rezeptoren als Angriffspunkte einer selektiven Chemotherapie. Pharmazie in unserer Zeit 24:14-26.
78. Kratz, F., Beyer, U., Collery, P., Lechenault, F., Cazabat, A., Schumacher, P., Falken, U., and Unger, C. 1998a. Preparation, characterization, and in vitro efficacy of albumin conjugates of doxorubicin. Biol. Pharm. Bull 21:56-61.
79. Kratz, F., Beyer, U., Roth, T., Schütte, M. T., Unold, A., Fiebig, H. H., and linger, C. 1998b. Albumin conjugates of the anticancer drug chlorambucil: Synthesis, characterization, and in vitro efficacy. Arch. Pharm. Pharm. Med. Chem. 331:47-53.
80. Kratz, F., Beyer, U., Roth, T., Tarasova, N., Collery, P., Lechenault, F., Cazabat, A., Schumacher, P., Unger, C., and Falken, U. 1998c. Transferrin conjugates of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro efficacy, J. Pharm. Sci. 87:338-346.
81. Kratz, F., Beyer, U., Schumacher, P., Krüger, M., Zahn, H., Roth, T., Fiebig, H. H., and Unger, C. 1997a. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg. Med. Chem. Lett. 7:617-622.
82. Kratz, F., Fichtner, I., Beyer, U., Schumacher, P., Roth, T., Fiebig, H. H., and Unger, C. 1997b. Antitumor activity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumour xenograft models. Eur. J. Cancer 33:784.
83. Kratz, F., Hartmann, M., Keppler, B. K., and Messori, L. 1994a. The binding properties of two ontitumor ruthenium(III) complexes to apotransferrin. J. Biol. Chem. 269:2581-2588.
84. Kratz, F., Keppler, B. K., Hartmann, M., Messori, L., and Berger, M. R. 1996. Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in a human colon cancer cell line. Metal-Based Drugs 3:15-23.
85. Kratz, F., Keppler, B. K., Messori, L., Smith, C., and Baker, E. N. 1994b. Protein-binding properties of two antitumour Ru(III) complexes to human apotransferrin and apolactoferrin. Metal-based Drugs 1:169-173.
86. Kratz, F., Mulinacci, N., Messori, L., Bertini, I., and Keppler, B. K. 1992. Kinetic, spectroscopic and LPLC studies of the interactions of antitumour ruthenium(III) complexes with serum proteins. In Metal Ions in Biology and Medicine, Vol. 2, 69-74, John Paris: John Libbey Limited Eurotext.
87. Kratz, F., Roth, T., Fiebig, H. H., and Unger, C. 1997c. Superior in vivo efficacy of an acid-sensitive albumin conjugate of doxorubicin in two human xenograft models. Annual Congress of the German and Swiss Pharmaceutical Society. Zurich, Switzerland P55.
88. Kratz, F., Roth, T., Fichtner, I., Fiebig, H. H., and Unger, C. 1998d. Development of antitumor protein and polymer conjugates using in vitro and in vivo tumor xenograft models. In Relevance of Tumor Models for Anticancer Drug Development, Contribution to Oncology, ed. H. H. Fiebig. Basel, Switzerland: Karger Verlag, in press.
89. Kratz, F., and Schütte, M. T. 1998. Anticancer metal complexes and tumor targeting strategies. Cancer J. 11:176-181.
90. Krieger, M., Brown, M. S., Faust, J. R., and Goldstein, J. L. 1978. Replacement of endogenous cholesteryl esters of low density lipoprotein with exogenous cholesteryl linoleate. J. Biol. Chem. 253:4093-4101.
91. Kritchevsky, S. B., Wilcosky, T. C., Morris, D. L., Truong, K. N., and Tyroler, H. A. 1991. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res. 51:3198-3203.
92. Krüger, M., Beyer, U., Schumacher, P., Unger, C., Zahn, H., and Kratz, F. 1997. Synthesis and stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of chemoimmunoconjugates. Chem. Pharm. Bull. 47:399-401.
93. Laurie, S. M., and Robbins, A. R. 1991. A toxin-resistant mouse L-cell mutant defective in protein transport along the secretory pathway. J. Cell Physiol. 147:215-223.
94. Lemieux, P., Pagé, M., and Noel, C. 1992. In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate. In Vivo 6:621-628.
95. Lombardi, P., Norata, C., Maggi, F. M., Canti, G., Franco, P. O., Nicolin, A., and Capatano, A. L. 1989. Assimilation of LDL by experimental tumours in mice. Biochim. Biophys. Acta 1003:301-306.
96. Lundberg, B. 1987. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. 47:4105-1108.
97. Lundberg, B. 1992. Assembly of prednimustine low-density lipoprotein complexes and their cytotoxic activity in tissue culture. Cancer Chemother. Pharmacol. 29:241-247.
98. Lundberg, B., and Suominen, L. 1984. Preparation of biologically active analogs of serum low density proteins. J. Lipid Res. 25:550-558.
99. Maeda, H., and Matsumura, Y. 1989. Tumoritropic and lymphotropic principles macromolecular prodrugs. Crit. Rev. Ther. Drug Carrier Sys. 6:193-210.
100. Masquelier, M., Vitols, S., and Peterson, C. 1986. Low-density lipoprotein as a carrier antitumoral drugs: In vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res. 46:3842-3847.
101. Matsumura, Y., and Maeda, H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins of the antitumor agent smancs. Cancer Res. 46:6387-6392.
102. Means, G. E., and Feeney, R. E. 1990. Chemical modification of proteins: History and application. Bioconjugate Chem. 1:2-12.
103. Messori, L., and Kratz, F. 1994. Transferrin - from inorganic biochemistry to medicine. Metal-based Drugs 1:161-167.
104. Mider, G. B., Tesluk, H., and Morton, J. J. 1948. Effects of Walker carcinoma 256 on food intake, body weight, and nitrogen metabolism of growing rats. Acta Union Int. Contra Cancrum 6:409-420.
105. Miller, S. R., Tauter, P. I., Papatestas, A. E., Slater, G., and Aufses, A. H., Jr. 1981. Serum cholesterol and human colon cancer. J. Natl. Cancer Inst. 67: 297-300.
106. Morimoto, Y., and Fujimoto, S. 1985. Albumin microspheres as drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2:19-63.
107. Mukherjee, S., Grosh, R. N., and Maxfield, F. R. 1997. Endocytosis. Physiol. Rev. 77:759-803.
108. Mukhopadhyay, A., Mukhopadhyay, B., and Basu, S. K. 1995. Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. FEBS Lett. 376:95-98.
109. Neville, D. M. Jr., Srinavasachar, K., Stone, R., and Scharff, J. 1989. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J. Biol. Chem. 264:14653-14661.
110. Norata, G., Canti, G., Ricci, L., Nicolin, A., Trezzi, E., and Capatano, A. L. 1984. In vivo assimilation of low-density lipoproteins by a fibrosarcoma tumour cell line in mice. Cancer Lett. 25:203-208.
111. Ohkawa, K., Hatano, T., Tsukada, Y., Matsuda, M. 1993a. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. Br. J. Cancer 67:274-278.
112. Ohkawa, K., Hatano, T., Yamada, K., Joh, K., Takada, K., Tsukada, Y., and Matsuda, M. 1993b. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53:4238-4242.
113. O'Keefe, D. O., and Draper, R. K. 1985. Characterization of a transferrin-diphtheria toxin conjugate. J. Biol. Chem. 260:932-937.
114. O'Keefe, D. O., and Draper, R. K. 1988. Two pathways of transferrin recycling evident in a variant of mouse LMTK-cells. Somat. Cell. Mol. Genet. 14:473-487.
115. Partridge, W. M. 1996. Brain drug delivery and blood-brain barrier transport. Drug Del. 3:99-115.
116. Peters, T., Jr. 1985. Serum albumin. Adv. Protein. Chem. 37:161-245.
117. Peterson, C., Vitols, S., Rudling, M., Blomgren, H., Edsmyr, F., and Skoog, L. 1985. Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells. Med. Oncol. Tumor Pharmacother. 2:143-147.
118. Porto, C., Moroni, M., Nastasi, G., Invemizzi, R., and Bobbio-Pallavicini, E. 1991. Hypocholesterolemia and acute myeloid leukemia (AML). Haematologica 76:348.
119. Raso, V., and Basala, M. 1984. A highly cytotoxic human transferrin-ricin. A chain conjugate used to select receptor-modified cells. J. Biol. Chem. 259:1143-1149.
120. Raso, V., and Lawrence, J. 1984. Carboxylic ionophores enhance the cytotoxic potency of ligand- and antibody-delivered ricin A chain. J. Exp. Med. 160:1234-1240.
121. Raso, V., Watkins, S. C., Slayter, H., and Fehrmann, C. 1987. Intracellular pathway of ricin A chain cytotoxins. Ann. N. Y. Acad. Sci. 507:172-186.
122. Roth, T., Fiebig, H. H., Eckert, C., Spitzmüller, B., Beyer, U., Schumacher, P., Unger, C., and Kratz, F. 1997. In vitro antitumor efficacy of acid labile transferrin conjugates of doxorubicin in ten human tumor xenografts. Proc. Amer. Assoc. Cancer Res. 38:2898.
123. Rybak, S. M., Saxena, S. K., Ackerman, E. J., and Youle, R. J. 1991. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem. 266:21202-21207.
124. Sands, H., Jones, P. L., Shah, A. S., Palme, D., Vessella, R. L., and Gallagher, B. M. 1988. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts. Cancer Res. 48:188-193.
125. Schilling, U., Friedrich, A., Sinn, H., Schrenk, H. H., Clorius, J. H., and Maier-Borst, W. 1990. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier - Part 2. Nucl. Med. Biol. 19: Int. J. Rad. Appl. Instrum. B:685-695.
126. Schaler, J., Fiebig, H. H., Sausville, E. A., and Burger, A. M. 1997. Characterization of vascular permeability in human tumor xenografts-identification of suitable tumor models to evaluate polymer conjugates. Int. Symposium "Relevance of Tumor Models for Anticancer Drug Development" P6, 15-17.10.1997, Tumor Biology Center, Freiburg, FRG.
127. Seymour, L. W. 1992. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Sys. 9:135-187.
128. Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., and Ouncon, R. 1995. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular carrier. Eur. J. Cancer 31A: 766-770.
129. Sinn, H., Schrenk, H. H., Friedrich, A., Schilling, U., and Maier-Borst, W. 1990. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part 1. Nucl. Med. Biol. 17: Int. J. Rad. Appl. Instrum. B:819-827.
130. Smith, C. A., Sutherland-Smith, A. J., Keppler, B. K., Kratz, F., and Baker, E. N. 1996. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin by high resolution X-ray crystallographic structure analysis. J. Bioinorg. Chem. 1:424-431.
131. Som, P., Oster, Z. H., Matsui, K., Guglelmi, G., Persson, B. R. R., Pellettieri, M. L., Srivastava, S. C., Richards, P., Atkins, H. L., and Brill, A. B. 1983. Ru-97-transferrin uptake in tumor and abscess. Eur. J. Nucl. Med. 8:491-494.
132. Srivastava, S. C., Richards, P., Meinken, G. E., Larson, S. M., and Grunbaum, Z. 1981. Tumor uptake of radioruthenium compounds. In Radiopharmaceuticals: Structure-Activity Relationship, ed. R. Spencer, 207-223, New York: Grune and Stratton.
133. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Schütt, S., Heene, D. L., and Maier-Borst, W. 1997a. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anti-Cancer Drugs 8:677-685.
134. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C. M., Hartung, G., Maier-Borst, W., and Heene, D. L. 1997. Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol. 26:77-100.
135. Stehle, G., Wunder, A., Sinn, H., Schrenk, H. H., Schütt, S., Frei, E., Hartung, G., Maier-Borst, W., and Heene, D. L. 1997b. Pharmacokinetics of methotrexatealbumin conjugates in tumor bearing rats. Anti-Cancer Drugs 8: 835-844.
136. Stjernholm, R. L. 1986. Platinum bound to transferrin for use in the treatment of breast tumors. US patent 4590001A 20, May 1986.
137. Stjemholm, R., Warner, F. W., Robinson, J. W., Ezekiel, E., and Katayama, N. 1978. Binding of platinum to human transferrin. Bioinorg. Chem. 9:277-280.
138. Subr, V., Strohalm, J., Ulbrich, K., and Duncan, R. 1992. Polymers containing enzymatically degradable bonds. XII. Release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymers. J. Controlled Release 18:123-132.
139. Sun, I. L., Sun, E. E., Crane, F. L., Morre, D. J., and Faulk, W. P. 1992. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. Biochim. Biophys. Acta 1105:84-88.
140. Sutherland, R., Delia, D., Schneider, C., Newmann, R., Kemshead, J., and Greaves, M. 1980. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA 78:4515-4519.
141. Takakura, Y., Fujita, T., Hashida, M., and Sezaki, H. 1987. Disposition and tumor localization of mitomycin C dextran conjugates in mice. Pharm. Res. 4:293-300.
142. Takakura, Y., Fujita, T., Hashida, M., and Sezaki, H. 1990. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:339-346.
143. Takakura, Y., and Hashida, M. 1994. Macromolecular drug carrier systems in cancer chemotherapy: Macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18:207-231.
144. Tanaka, T., Kaneo, Y., and Iguchi, S. 1991. Properties of mitomycin C-protein conjugates in vitro and in vivo. Bioconjugate Chem. 2:261-269.
145. Tanaka, T., Kaneo, Y., and Miyashita, M. 1996. Synthesis of transferrin-mitomycin C conjugate as a receptor-mediated drug targeting system. Biol. Pharm. Bull. 19:774-777.
146. Tanaka, T., Kaneo, Y., Shiramoto, S., and Iguchi, S. 1993. The disposition of serum proteins as drug carriers in mice bearing sarcoma 180. Biol. Pharm. Bull. 16:1270-1275.
147. Testa, U., Pelosi, E., and Peschle, C. 1993. The transfenin receptor. Crit. Rev. Oncogenesis 4:241-276.
148. Trouet, A., Masquelier, M., Baurain, R., and Campeneere, D. D.-D. 1982. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolaseed, as required for a lysosomotropic drug carrier conjugate: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 79:626-629.
149. Trowbridge, I. S. 1988. Transferrin receptor as a potential therapeutic agent. Prog. Allergy 45:121-146.
150. Trowbridge, I. S., and Omary, M. B. 1981. Human cell surface glycoprotein related to the cell proliferation is the receptor for transfenin. Proc. Natl. Acad. Sci. USA 78:3039-3043.
151. Urushizaki, I. 1989. Targeting effect of transferrin-neocarzinostatin conjugate by receptor-mediated endocytosis. Nippon Rinsho - Japan. J. Clin. Med. 47: 1423-1431.
152. Versluis, A. J., van Geel, P. J., Oppelaar, H., van Berkél, T. J. C., and Bijsterbosch, M. K. 1996. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer 74:525-532.
153. Vitols, S. 1991. Uptake of low-density lipoprotein by malignant cells - possible therapeutic applications. Cancer Cells 3:488-495.
154. Vitols, S., Gahrton, G., Öst, Å., and Peterson, C. 1984. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 63:1186-1193.
155. Vitols, S., Söderberg-Reid, K., Masquelier, M., Sjöström, B., and Peterson, C. 1990. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex. Br. J. Cancer 62:724-729.
156. Wagner, E., Curiel, D., and Cotten, M. 1994. Delivery of drugs, proteins and genes into cells using transferrin as ligand for receptor-mediated endocytosis. Adv. Drug Del. Rev. 14:113-135.
157. Walsh, M. T., Ginsburg, G. S., Small, D. M., and Atkinson, D. 1982. Apo B-lecithin-cholesterol ester complexes: Reassembly of low density lipoprotein. Arteriosclerosis 2:445a.
158. Ward, S. G., and Taylor, R. C. 1988. Anti-tumor activity of the main-group metallic elements: Aluminium, gallium, thallium, germanium, lead, antimony and bismuth. In Metal-based Antitumor Drugs, Chapter 1. ed. M. F. Gielen, London: Freund Publishing House Ltd.
159. Warner, F. W., Demanuelle, M., Stjemholm, R., Cohn, I., and Baddley, W. H. 1977. Response to transferrin bound iron to treatment of rat lymphosarcoma with cisdichlorodiammine-platinum(II). J. Clin. Hematol. Oncol. 7:180-189.
160. White, S., Taetle, R., Seligman, P. A., Rutherford, M., and Trowbridge, I. S. 1991. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res. 50:6295-6301.
161. Wunder, A., Stehle, G., Sinn, H., Schrenk, H. H., Hoff-Biederbeck, D., Bader, F., Friedrich, E. A., Peschke, P., Maier-Borst, W, and Heene, D. L. 1997. Enhanced albumin uptake by rat tumors. Int. J. Oncol. 11:497-507.
162. Yeh, C. J., and Faulk, W. P. 1984. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin. Clin. Immunol. Immunopath. 32:1-11.
163. Yuan, F., Deilian, M., Fukumura, D., Leuning, M., Berk, D. A., Torchilin. V. P., and Jain, R. K. 1995. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 55:3752-3756.
164. Zyada, L. E., Hassan, H. T., Rees, J. K. H., and Ragab, M. H. 1990. The relation between hypocholesterolemia and degree of maturation of in acute myeloid leukemia. Hematol. Oncol. 8:65-69.